IASO Bio's first-in-human Phase 1 data for the dual-targeted BCMA/GPRC5D CAR-T RD140 could redefine treatment for high-risk multiple myeloma, building on a pipeline that already includes FDA-cleared in vivo CAR-T assets
Executive summary: IASO Bio presented first-in-human Phase 1 data for RD140, a fully human BCMA/GPRC5D dual-targeted FasT CAR-T, at the 2026 IMS meeting, involving 9 heavily pretreated high-risk patients with relapsed/refractory multiple myeloma or plasma cell leukemia. Dual-targeting BCMA and GPRC5D may improve efficacy and reduce relapse in the hardest-to-treat multiple myeloma patients, a key unmet need in CAR-T therapy. Early safety and efficacy results will determine whether RD140 can compete with established single-target CAR-T products.
Who is involved: IASO Bio, the International Myeloma Society (IMS), and the 9 patients in the study; C4 Therapeutics is also relevant, presenting competing multiple myeloma data at the same meeting.
Likely next: IASO Bio will likely advance RD140 into larger studies if safety and efficacy hold; details from the poster discussion may inform next steps and potential partnership interest.
IASO Bio presented first-in-human Phase 1 data for RD140, a fully human BCMA/GPRC5D dual-targeted FasT CAR-T, in 9 heavily pretreated high-risk patients with relapsed/refractory multiple myeloma or plasma cell leukemia. The poster was selected for a poster discussion session at the 2026 IMS meeting, indicating peer interest in the dual-targeting approach. The data are early, but they underscore the company's push to differentiate its CAR-T platform in a crowded multiple myeloma treatment landscape.
What's next — scenarios
Base: continued development toward Phase 2 (60%)
RD140 advances into a larger dose-expansion trial, reinforcing IASO Bio's CAR-T pipeline for multiple myeloma.
- Publication of detailed poster data at IMS
- IASO Bio's next press release on RD140
Upside: accelerated path due to strong efficacy (25%)
High response rates in these 9 patients could prompt expedited regulatory engagement and partnership interest.
- If poster discussion highlights deep, durable responses
- IASO Bio announces a partnership or licensing deal for RD140
Downside: safety or efficacy concerns slow program (15%)
A poor risk-benefit profile could halt the program or pivot to combination strategies.
- If conference Q&A reveals unacceptable toxicity
- IASO Bio redirects resources to other pipeline candidates like IASO208
What to watch
- Presentation materials from the 2026 IMS poster discussion session (Abstract PA-200) expected to be released online within days.
- IASO Bio's next corporate presentation or press release mentioning RD140 within 30-60 days.
- Any updated FUMANBA-1 analysis disclosures on FUCASO in next quarter that may reflect on dual-targeting efficacy.
- Observations from clinicaltrials.gov for new RD140 trial registrations within 90 days.
Timeline
- — 2026 IMS | IASO Bio Presents First-in-Human Phase 1 Data of RD140, a Fully Human BCMA/GPRC5D Dual-Targeted FasT CAR-T (PR Newswire)
- — 2026 IMS | Updated FUMANBA-1 Analysis of IASO Bio's FUCASO Reveals That In Vivo Durable Persistence of CAR-T Cells Is Associated with Sustained MRD Negativity and Delayed Disease Progression (PR Newswire)
- — C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting (GlobeNewswire)
- — IASO Bio's CD20-Targeted In Vivo CAR-T Therapy IASO208 Receives FDA IND Clearance (PR Newswire)
- — IASO Biotechnology Announces Acquisition of Singapore-Based Cell Therapy Company MediSix Therapeutics (PR Newswire)
Analysis — what this means
Sectors affected
- CAR-T cell therapy
- Multiple myeloma therapeutics
- Precision oncology
Regulatory implications
- IASO208's FDA IND clearance demonstrates IASO Bio can navigate the US regulatory process for CAR-T products, a relevant precedent for RD140's development path.
Key entities
Sources
- 2026 IMS | IASO Bio Presents First-in-Human Phase 1 Data of RD140, a Fully Human BCMA/GPRC5D Dual-Targeted FasT CAR-T — PR Newswire
- 2026 IMS | Updated FUMANBA-1 Analysis of IASO Bio's FUCASO Reveals That In Vivo Durable Persistence of CAR-T Cells Is Associated with Sustained MRD Negativity and Delayed Disease Progression — PR Newswire
- IASO Bio's CD20-Targeted In Vivo CAR-T Therapy IASO208 Receives FDA IND Clearance — PR Newswire
- IASO Biotechnology Announces Acquisition of Singapore-Based Cell Therapy Company MediSix Therapeutics — PR Newswire
- C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting — GlobeNewswire
Related cases
- LexisNexis and IMS launch edge-computing telematics to advance insurance intelligence beyond traditional UBI
- IASO Bio secures FDA clearance for first China-origin lentiviral in vivo CAR-T therapy
- Triple B Media expands FAST channel ecosystem through partnership with Silver Sports & Entertainment for live NHL content
- Japan launches its first full-stack neutral-atom quantum computer, Shunkai, boosting national quantum capabilities
- FAST funds Frances Arnold’s directed‑evolution platform to create RNA‑targeted nucleoside analogs for Angelman syndrome therapy